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OBJECTIVE—Chronic hypoxia has been recognized as a key
regulator in renal tubulointerstitial ﬁbrosis, as seen in diabetic
nephropathy, which is associated with the activation of hypoxia-
inducible factor (HIF)-1a. We assess here the effects of the biguanide,
metformin, on the expression of HIF-1a in diabetic nephropathy
using renal proximal tubular cells and type 2 diabetic rats.
RESEARCH DESIGN AND METHODS—We explored the
effects of metformin on the expression of HIF-1a using human
renal proximal tubular epithelial cells (HRPTECs). Male Zucker
diabetic fatty (ZDF; Gmi-fa/fa) rats were treated from 9 to 39
weeks with metformin (250 mg $ kg
21 $ day
21) or insulin.
RESULTS—Metformin inhibited hypoxia-induced HIF-1a accumu-
lation and the expression of HIF-1–targeted genes in HRPTECs.
Although metformin activated the downstream pathways of
AMP-activated protein kinase (AMPK), neither the AMPK acti-
vator, AICAR, nor the mTOR inhibitor, rapamycin, suppressed
hypoxia-induced HIF-1a expression. In addition, knockdown of
AMPK-a did not abolish the inhibitory effects of metformin on
HIF-1a expression. The proteasome inhibitor, MG-132, completely
eradicated the suppression of hypoxia-induced HIF-1a accumula-
tion by metformin. The inhibitors of mitochondrial respiration sim-
ilarly suppressed hypoxia-induced HIF-1a expression. Metformin
signiﬁcantly decreased ATP production and oxygen consumption
rates, which subsequently led to increased cellular oxygen tension.
Finally, metformin, but not insulin, attenuated tubular HIF-1a
expression and pimonidazole staining and ameliorated tubular
injury in ZDF rats.
CONCLUSIONS—Our data suggest that hypoxia-induced HIF-
1a accumulation in diabetic nephropathy could be suppressed by
the antidiabetes drug, metformin, through the repression of oxy-
gen consumption. Diabetes 60:981–992, 2011
D
iabetic nephropathy now is a leading cause of
end-stage renal failure and therefore constitutes
a major component of progressive kidney dis-
ease. Chronic hypoxia and tubulointerstitial ﬁ-
brosis presently are considered to be common pathways
for various progressive kidney diseases, including diabetic
nephropathy, and hypoxia-inducible factor (HIF)-1a plays
an important role in these pathological mechanisms (1–4).
Recent studies (4–6) have demonstrated that hypoxia
represents an early event in the development and pro-
gression of diabetic nephropathy and an increase in HIF-1a
expression in diabetic kidneys compared with the kidneys
of control rats (7) and normal human kidneys (8). In ad-
dition, Higgins et al. (8) have demonstrated that HIF-1a
enhanced the epithelial-to-mesenchymal transition (EMT)
in vitro and that genetic ablation of renal epithelial HIF-1a
inhibited the development of tubulointerstitial ﬁbrosis us-
ing HIF-1a knockout mice. Sun et al. (9) further provided
a novel explanation for the EMT of hypoxic renal tubular
cells through the upregulation of Twist induced by HIF-1a.
Kimura et al. (10) recently showed that stable expression
of HIF-1a in tubular epithelial cells promotes interstitial
ﬁbrosis in knockout mice with von Hippel-Lindau (VHL)
tumor suppressor, which acts as an ubiquitin ligase to
promote proteolysis of HIF-a.
Metformin has been widely used for treating type 2 di-
abetes without the stimulation of insulin production, and,
for this reason, it is considered an insulin sensitizer (11).
The UK Prospective Diabetes Study (UKPDS) showed that
metformin could reduce macrovascular morbidity and
mortality (12), suggesting that it achieved its antiath-
erogenic and anti-inﬂammatory effects by means of anti-
oxidant properties (13). Moreover, metformin signiﬁcantly
decreased the urine albumin excretion rate in patients
with type 2 diabetes (14). The beneﬁts of metformin with
regard to the risk of cardiovascular outcomes and meta-
bolic parameters suggest its clinical use in treating chronic
kidney disease (15). The precise mechanisms beyond the
effects of metformin on glucose still are obscure. Recently,
metformin has been found to activate AMP-activated pro-
tein kinase (AMPK), a major cellular regulator of lipid and
glucose metabolism (16,17), via a liver kinase B1 (LKB1)-
dependent mechanism (18). The LKB1-AMPK–mammalian
target of rapamycin (mTOR) pathway is a key regulator of
HIF-1–targeted genes and HIF-1–mediated cellular metab-
olism (19–21). In addition, a recent study (22) has shown
that metformin inhibits insulin and IGF-1–induced HIF-1a
expression in nontumor retinal epithelial ARPE-19 cells.
This evidence led us to question whether metformin,
known as an AMPK activator, might regulate the expres-
sion of HIF-1a protein in renal proximal tubular cells.
Therefore, we investigated the effects of metformin on
HIF-1a expression using cultured human renal proximal
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ORIGINAL ARTICLEtubular epithelial cells (HRPTECs) and Zucker diabetic
fatty (ZDF) rats, a model of type 2 diabetes (23).
RESEARCH DESIGN AND METHODS
Metformin was provided by Dainippon Sumitomo Pharma (Osaka, Japan).
AICAR, MG-132, and rapamycin were purchased from Calbiochem (San Diego,
CA). Anti–AMPK-a,a n t i –AMPK-a1, anti–AMPK-a2, anti–phosphorylated (p)-
AMPK-a (Thr172), anti–p-acetyl-CoA carboxylase (ACC) (Ser79), and anti–p-
mTOR (Ser2448) antibodies were obtained from Cell Signaling Technology
(Beverly, MA). The primary antibodies are monoclonal mouse antibodies for
human HIF-1a (BD Biosciences, Benford, MA) and for rat HIF-1 a (Novus
Biological, Littleton, CO). D-glucose was purchased from Wako Pure Chemical
Industries (Osaka, Japan). ON-TARGETplus SMARTpool siControl (D-001810),
AMPK-a1 (NM-006251), AMPK-a2 (NM-006252), and small-interference RNAs
(siRNAs) were purchased from Dharmacon (Lafayette, CO). Alexa Fluor 594
donkey anti-mouse secondary antibody was purchased from Invitrogen (Gai-
thersburg, MD). Other chemicals and antibodies were obtained from Sigma-
Aldrich (St. Louis, MO), unless otherwise indicated.
Human renal proximal epithelial tubular cell cultures. Human proximal
tubular epithelial cells (HPRTECs) were purchased as once- or twice-passaged
tubular cells from Lonza Walkersville (Walkersville, MD). The tubular cells
were cultured in renal epithelial cell growth medium, according to the man-
ufacturer’s instructions, as described before (24). After 24 h of starvation with
serum-free DMEM, the cells were exposed to reagents under normoxic (21%
O2) or hypoxic (1% O2) conditions for ~4–24 h and were then harvested for
experiments. In all, experiments were deprived of serum.
RNA isolation, RT-PCR, and real-time RT-PCR. Total RNA extraction and
cDNA synthesis were preformed as described previously (24). Each cDNA
sample was analyzed for gene expression by quantitative real-time PCR with
an ABI 7300 Sequence Detector (Applied Biosystems, Foster City, CA) using
the TaqMan Universal PCR Master Mix (Applied Biosystems), as described
previously (24). Unlabeled speciﬁc primers were purchased from Applied
Biosystems for detecting the human plasminogen activator inhibitor (PAI)-1
(Serpine) gene (assay ID no. HS00167155-ml), the human SLC2A1 gene (assay
ID no. HS00197884-ml), the human HIF-1a gene (assay ID no. HS00153153-
ml), the human vascular endothelial growth factor (VEGF) gene (assay ID no.
HS00900054-ml), and the 18S gene (assay ID no. HS 9999991-sl).
siRNA and HRPTEC transfection. Silencing of AMPK-a1/-a2 gene expres-
sion in HRPTECs was achieved by the siRNA technique, as described pre-
viously (24). Forty-eight hours after transfection, HRPTECs were serum
starved for an additional 24 h and subsequently treated as indicated.
Protein extraction and Western blot analysis of intracellular proteins
in HRPTECs. Total cellular extracts from HRPTECs were prepared, and
Western blot was carried out using a denaturing 8% Novex Tris-glycine gels
(Invitrogen, Carlsbad, CA) or 10% NuPage Bis-Tris SDS-PAGE gels under re-
ducing conditions, as described previously (24). Membranes were washed and
reprobed with an antibody against a-actinin (Sigma) to control for small
variations in protein loading and transfer. Images were acquired using the
Adobe Photoshop program (Adobe Systems, San Jose, CA) and processed
using Multi Guage (Fuji Film, Tokyo, Japan) for densitometric analysis. Signal
intensities in control lanes were arbitrarily assigned a value of 1.00.
Oxygen consumption measurements. Cells were incubated under normoxic
(21% O2) or hypoxic (1% O2) conditions in medium containing 5.5 mmol/L
(low) or 25 mmol/L (high) glucose and then resuspended in normoxic medium.
Average oxygen consumption rates in HRPTECs treated with reagents in
normoxia or hypoxia for 4 h were measured in a sealed chamber using a Clark-
type electrode.
Measurement of cell ATP. HRPTECs were incubated with reagents under
normoxic or hypoxic conditions for 4 h. ATP production was monitored by
glucose-6-phosphate formation. Brieﬂy, cells were extracted with perchloric
acid (6%) and centrifuged (8,000g for 10 min). Subsequently, the extract was
neutralized with K2CO3 (5 mol/L) neutralized to pH 7. NADP
+ (0.5 mmol/L) and
glucose 6-phosphate dehydrogenase (0.25 units) were then added and ATP
production was monitored from the NADPH content by spectrophotometry at
340 nm. Cell proteins were determined in parallel dishes for the normalization
of the ATP values.
Imaging of reactive oxygen species. The oxidative ﬂuorescent dihy-
droethidium (DHE) (Sigma) was used to evaluate the intracellular production
of superoxide (O2
2) (25). In brief, after incubation overnight, cells with or
without 1 mmol/L metformin or 1 mmol/L AICAR under normoxic and hypoxic
conditions were washed with serum-free and phenol-red–free DMEM and
loaded with 5 mmol/L DHE. After incubation for 10 min in the dark, the cells
were washed with PBS and were subjected to ﬂuorescence microscopy.
NADPH content. NADPH content was determined using a NADP/NADPH
Quantiﬁcation kit (BioVision, Mountain View, CA) and the protocol supplied by
the manufacturer.
Immunocytochemistry.HRPTECswereculturedonfour-chamberglassslides
(BD Biosciences) to reach 80% conﬂuence. After exposure to 1 mmol/L met-
formin or 1 mmol/L AICAR for 4 h under normoxic or hypoxic conditions, the
cells were ﬁxed with 100% ethanol for 10 min and were incubated with an anti–
HIF-1a antibody (1:100; BD Biosciences) at 4°C overnight. Then, cells were
rinsed in PBS and subsequently incubated with Alexa Fluor 594 donkey anti-
mouse secondary antibody (Invitrogen) at 1:200 dilution overnight at 4°C.
Finally, slides were analyzed by cofocal laser–scanning microscopy.
Detection of cellular hypoxia. Cellular hypoxia was detected by adding
pimonidazole hydrochloride (200 mmol/L hypoxyprobe-1; Hydroxyprobe,
Burlington, MA), which binds to cells or tissues with pO2 levels ,10 mmHg, to
HRPTECs that were treated with 1 mmol/L metformin or 1 mmol/L AICAR and
exposed to hypoxia (1% O2) for 4 h. To detect hypoxic conditions in each
group of rats, pimonidazole (60 mg/kg) was injected intraperitoneally 1 h
before they were killed. Staining was performed according to the manu-
facturer’s instructions.
Animals. Male ZDF/Gmi-fa/fa rats and their heterozygous (ZDF/Gmi-+/fa) lean
littermates were purchased from Charles River Japan. Animals purchased at 7
weeks of age were given an ad libitum commercial pellet diet (CE-2; CLEA,
Tokyo, Japan) and tap water. ZDF rats were randomly assigned to four groups
at the age of 9 weeks. A ﬁrst group did not receive an active pharmacological
treatment and was used as a control (ZDF control). A second group received
metformin in standard diet at a concentration of 3.3 g/kg (ZDF+M group).
Taking into account an average daily food intake of 32.4 g per rat, a dose of
~253.2 mg $ kg
21 $ day
21 was achieved. The metformin dose is compatible
with those used in previous studies in rats (26,27). A third group was treated
with a sustained-release insulin implant (~2 units per day per implant) (ZDF+I
group) (Lin Shin Canada, Ontario, Canada). Heterozygous animals without
active treatment were used as nondiabetic, lean controls (ZL group). Tail
postprandial glucose in whole blood was quantiﬁed using a glucose analyzer
(One Touch; Life Scan, Johnson & Johnson, Milpitas, CA). Hemoglobin A1c was
measured using the DCA 2000 analyzer (Siemens Medical Solutions Diagnostics,
Tokyo, Japan). Renal function was assessed by measuring urinary albumin
excretion. Urinary albumin was quantiﬁed using the Nephrat kit (Exocell,
Philadelphia, PA), according to manufacturer’s instructions. Animals were killed
at the age of 17 weeks for pimonidazole staining and at the age of 39 weeks for
assessment of morphology and immunohistochemistry for HIF-1a by over-
anesthetization with isoﬂurane and cardiac puncture. The kidneys were ﬁxed
with perfusion, as described in a previous study (28). The Asahikawa Medical
College Research Center for Animal Life Science approved all experiments.
Morphological analysis and immunohistochemistry. To evaluate HIF-1a or
pimonidazole expression in the kidney, immunohistochemistry was performed
with mouse monoclonal anti–HIF-1a antibody (ESEE 122, 1:100) or mouse
antipimonidazole (1:1000), as described previously (24). The positive immu-
noreactivity for nuclear HIF-1a protein or cytosolic pimonidazole was esti-
mated as absent (0) for 0%, low (1) for 1–20%, intermediate (2) for 21–50%, and
high (3) for more than 50% of the tubular cells in the juxtamedullary cortical
and outer medullar regions. Assessment of tubulointerstitial injury was eval-
uated in the juxtamedullary cortical and outer medullar regions using periodic
acid–Schiff staining and a semiquantitative scoring system evaluating in-
terstitial ﬁbrosis, inﬂammation, tubular atrophy, tubular dilation, debris ac-
cumulation, and cast formation. A score of 0 means normal tubulointerstitium,
1 means injury in ,25%, 2 means injury in up to 50%, and 3 means injury in
.50% of the biopsy specimen.
Statistical analysis. Three separate experiments at least were performed per
protocol. Each treatment group was assayed in duplicate for real-time RT-PCR.
The values shown represent the means 6 SD. Statistical analysis was per-
formed by ANOVA and Bonferroni post hoc tests. Values of P , 0.05 were
considered statistically signiﬁcant.
RESULTS
Metformin inhibits hypoxia-induced HIF-1a protein
accumulation. We investigated the impact of metformin
on hypoxia-induced HIF-1a expression. HRPTECs faintly
expressed HIF-1a protein under normoxic condition (Fig.
1A). The treatment of hypoxia (1% O2) markedly induced
HIF-1a protein accumulation in HRPTECs, and metformin,
at the concentration of 1 mmol/L, inhibited hypoxia-
induced HIF-1a protein expression (Fig. 1A). Densitometric
analysis showed that hypoxia signiﬁcantly induced HIF-1a
protein expression compared with the control in normoxia
(P , 0.01) and a signiﬁcant ~85% attenuation in hypoxia-
induced HIF-1a protein accumulation in HRPTECs treated
with 1 mmol/L metformin, compared with hypoxia-treated
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metformin was detected at the concentration of 10 mmol/L,
which was a therapeutic concentration as described in
previous studies (11,29) (Fig. 1C and D), and for the
incubation time of ~4–24 h (data not shown). In contrast,
HIF-1a mRNA levels were not reduced by metformin in
hypoxia, suggesting that metformin decreased HIF-1a
protein via posttranslational mechanisms (Fig. 1E).
FIG. 1. A: Metformin inhibits hypoxia-induced HIF-1a protein expression. HRPTECs were treated with 1 mmol/L metformin and 1 mmol/L AICAR
under normoxic and hypoxic conditions overnight. Whole-cell protein extracted from HRPTECs was analyzed by Western blot analysis. Although
AICAR stimulated the phosphorylation of AMPK and ACC and inhibited the phosphorylation of mTOR much like metformin, AICAR failed to
suppress hypoxia-induced HIF-1a expression. B: Metformin inhibits hypoxia-induced HIF-1a protein expression. HRPTECs were treated with or
without 1 mmol/L metformin under normoxic (21% O2) and hypoxic (1% O2) conditions overnight. Whole-cell proteins were extracted and analyzed
for HIF-1a expression by Western blot. Metformin inhibited hypoxia-induced HIF-1a expression. Densitometric analysis showed that hypoxia
signiﬁcantly induced HIF-1a protein expression compared with that in control in normoxia and that metformin decreased hypoxia-induced HIF-1a
expression to ~15.4% of that of control in hypoxia. ##P < 0.01 vs. control under normoxic conditions; **P < 0.01 vs. control under hypoxic
conditions. C: Metformin inhibits hypoxia-induced HIF-1a accumulation. HRPTECs were incubated in serum-free DMEM with 0.01–1 mmol/L
metformin under hypoxic conditions. After 4 h, cells were harvested for Western blot analysis. D: The inhibitory effect of metformin on hypoxia-
induced HIF-1a expression was signiﬁcantly detectable at 0.01 mmol/L. **P < 0.01 vs. control under hypoxic conditions; $$P < 0.01 vs. 0.01 mmol/L
metformin-treated cells under hypoxic conditions. E–H: Quantitative real-time RT-PCR analysis of HIF-1a and HIF-1 target genes. HRPTECs were
treated with or without 10 mmol/L metformin under normoxic and hypoxic conditions overnight. Then, total RNA was extracted from HRPTECs
and was applied for quantitative RT-PCR. The relative amounts of PAI-1, VEGF, and Glut-1 mRNA were normalized by 18S and expressed as an
arbitrary unit in which the control group value equaled 1. Hypoxia signiﬁcantly induced PAI-1, VEGF, and Glut-1 mRNA expression in HRPTECs,
and 10 mmol/L metformin inhibited the induction of this mRNA expression by hypoxia. Data represent means 6 SD (n =3 ) .# # P < 0.01 vs. control
under normoxic conditions; *P < 0.05; **P < 0.01 vs. control under hypoxic conditions.
Y. TAKIYAMA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 983Metformin inhibits hypoxia-induced PAI-1, VEGF, and
Glut-1 mRNA expressions. We examined the effects of
metformin on the expression of HIF-1 target genes in
HRPTECs (Fig. 1F–H). Real-time PCR results showed that
hypoxia signiﬁcantly promoted PAI-1, VEGF,a n dGlut-1
gene expression in HRPTECs. Treatment with 10 mmol/L
metformin signiﬁcantly reduced the enhancing effects of
hypoxia on these mRNA expressions.
Metformin inhibits hypoxia-induced HIF-1a expression
independent of AMPK. As shown in Fig. 1A and C,
metformin inhibited hypoxia-induced HIF-1a protein accu-
mulation in HRPTECs, accompanied by increased AMPK-a
FIG. 2. Metformin inhibited hypoxia-induced HIF-1a protein expression independent of AMPK. A–D: HRPTECs were transiently transfected with
control, AMPK-a1–,o r- a2–speciﬁc siRNAs (25 nmol/L ﬁnal concentration). Forty-eight hours after transfection, cells were serum starved for an
additional 24 h and subsequently treated as indicated under normoxic or hypoxic conditions for 4 h, and cells were lysed and subjected to im-
munoblotting with speciﬁc antibodies indicated. Lowering AMPK-a1( A and B) or AMPK-a2( C and D) protein expression with speciﬁc siRNA
failed to restore the inhibitory effects of metformin on hypoxia-induced HIF-1a protein expression. #P < 0.05; ##P < 0.01 vs. nontreated cells;
*P < 0.05; **P < 0.01 vs. control siRNA-transfected cells; $P < 0.05; $$P < 0.01 vs. AMPK-a1o r- a2 siRNA-transfected cells under hypoxic
conditions. E: The proteasomal inhibitor MG-132 (10 mmol/L) abolished the inhibitory effect of 10 mmol/L metformin on HIF-1a accumulation
under hypoxic conditions for 4 h. Although an AMPK inhibitor, compound C (20 mmol/L) failed to antagonize the inhibitory effect of metformin on
HIF-1a protein expression.
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an AMPK activator, AICAR, on hypoxia-induced HIF-1a
expression (Fig. 1A). Although AICAR stimulated the
phosphorylation of AMPK and ACC and inhibited the
phosphorylation of mTOR-like metformin under normoxic
and hypoxic conditions, AICAR failed to suppress hypoxia-
induced HIF-1a expression (Fig. 1A). To study the role of
AMPK on the inhibitory effects of metformin on HIF-1a
expression, we have taken a genetic approach to inhibit
the AMPK activity under hypoxic conditions. Immunoblots
using antiphosphorylated (Thr172)-AMPK-a1 and -a2a n -
tibody increased signiﬁcantly in response to metformin
dose dependently in siAMPK-a1–treated cells, suggesting
that the presence of AMPK-a2 compensated for the absence
of AMPK-a1( F i g .2 A). In contrast, total p–AMPK-a content
was markedly suppressed in siAMPK-a2–transfected cells
treated with metformin (Fig. 2C), indicating that metfor-
min could predominantly augment the phosphorylation of
AMPK-a2 in HRPTECs, which was consistent with the
previous study (30) investigating the effects of AICAR,
hypoxia, and rotenone on isoform-speciﬁcA M P Ka c t i v i t y .
Thus, lowering the AMPK-a protein using speciﬁc siRNA for
AMPK-a1o r- a2 did not affect hypoxia-induced HIF-1a
expression and failed to abolish the inhibitory effects
of metformin on hypoxia-induced HIF-1a expression
(Fig. 2A–D).
Proteasomal inhibitor MG-132 pretreatment restores
the inhibitory effects of metformin on hypoxia-induced
HIF-1a expression. To examine the posttranslational reg-
ulation of HIF-1a protein by metformin, we used the pro-
teasomal inhibitor MG-132. As shown in Fig. 2E, MG-132
restored the inhibitory effect of metformin on hypoxia-
induced HIF-1a accumulation, indicating that metformin
exhibited its inhibitory effect on HIF-1a accumulation
by promoting proteasomal HIF-1a degradation. Although
an AMPK inhibitor, compound C (20 mmol/L) failed to
FIG. 3. Effects of high glucose on the inhibitory effects of metformin on hypoxia-induced HIF-1a expression. A: HRPTECs were treated with high
D-glucose (25 mmol/L) and 1 mmol/L metformin under normoxic and hypoxic conditions overnight. Whole-cell proteins extracted from HRPTECs
were then analyzed by Western blot. Although high glucose attenuated the stimulatory effects of metformin on the expression of p-AMPK and
p-ACC and the inhibitory effects of metformin on the expression of p-mTOR, high glucose did not blunt the inhibitory effect of metformin on
HIF-1a expression. L-glucose (25 mmol/L) as an osmolarity control also did not alter the effects of metformin. B: Densitometric analysis showed
that high glucose did not affect HIF-1a protein expression in hypoxia and that metformin still decreased hypoxia-induced HIF-1a expression to
>80% of that of control in hypoxia independent of glucose concentrations. **P < 0.01.
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hypoxia-induced HIF-1a. HRPTECs were treated with inhibitors of mitochondrial pyruvate transport (0.1 mmol/L CHC), mTOR (100 nmol/L
rapamycin), and with 1 mmol/L metformin under normoxic and hypoxic conditions for 4 h. These inhibitors failed to decrease hypoxia-induced HIF-
1a accumulation. B: The inhibitors for mitochondrial respiratory complexes I and III inhibit hypoxia-induced HIF-1a accumulation. The cells were
treated with mitochondrial respiratory complex I (0.25 mmol/L, 25 mmol/L rotenone), mitochondrial respiratory complex III (10 ng/mL, 1 mg/mL
antimycin A), and with 1 mmol/L metformin under hypoxic conditions for 4 h. The inhibition of mitochondrial respiration suppressed HIF-1a
protein expression, accompanied with increased expressions of p-AMPK and p-ACC, and decreased p-mTOR expression. C and D: Metformin
suppressed mitochondrial respiratory functions of HRPTECs in normoxia and hypoxia in medium containing 5.5 mmol/L (low) (C) or 25 mmol/L
(high) (D) glucose. Cells treated with indicated reagents were incubated in normoxia (21% O2) or hypoxia (1% O2) for 4 h and then resuspended in
normoxic medium. Oxygen consumption was measured in a sealed chamber using a Clark-type electrode. C: Hypoxia decreased oxygen con-
sumption down to 76.5% of the control in normoxia in low glucose (**P < 0.01) (C). D: This response to hypoxia was blunted by 25 mmol/L glucose.
Metformin signiﬁcantly inhibited oxygen consumption to <50% of controls, independent of the oxygen conditions or the glucose milieu (*P < 0.05;
**P < 0.01). Data are expressed as means 6 SD (n =3 ) .E and F: Cell ATP during metformin or AICAR treatment under normoxia and hypoxia in
medium containing 5.5 mmol/L (low) (E) or 25 mmol/L (high) (F) glucose. HRPTECs were incubated with indicated reagents in normoxia or
hypoxia for 4 h. At the end of incubation, cells were extracted with perchloric acid for the measurement of ATP as described in RESEARCH DESIGN AND
METHODS. Protein was determined in parallel dishes. Cell ATP was normalized with protein. Data are expressed as means 6 SD (n = 3). E:T h e
METFORMIN INHIBITS HIF-1a EXPRESSION
986 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.organtagonize the inhibitory effect of metformin on HIF-1a
protein expression (Fig. 2E).
High glucose does not affect the inhibitory effects of
metformin on hypoxia-induced HIF-1a expression. As
shown in Fig. 3A, high glucose attenuated the stimulatory
effects of metformin on the phosphorylation of AMPK-a
and ACC and restored the inhibitory effect of metformin
on p-mTOR expression. These results were similar to those
of a recent study (31) in diabetic rats. However, the
treatment of high glucose did not blunt the inhibitory ef-
fect of metformin on HIF-1a expression (Fig. 3A and B),
concomitantly suggesting that the activation of AMPK-a
is insufﬁcient for the inhibitory effect of metformin on
hypoxia-induced HIF-1a expression.
Mitochondrial respiratory complex inhibitors, but not
rapamycin, mimic the actions of metformin on AMPK
activation and hypoxia-induced HIF-1a expression.
To determine the mechanism implicated in the regula-
tion of HIF-1a expression in HRPTECs, subsequent
experiments were achieved by the use of inhibitors of
mitochondrial pyruvate transport (0.1 mmol/L a-cyano-4-
hydroxycinnamate [CHC]), mTOR (100 nmol/L rapamycin),
mitochondrial respiratory complex I (0.25 mmol/L, 25 mmol/L
rotenone), and mitochondrial respiratory complex III
(10 ng/mL, 1 mg/mL antimycin A). The expression of HIF-1a
induced by hypoxia was unaffected by CHC and rapamycin
(Fig. 4A), whereas it was completely blocked by rotenone
and antimycin A (Fig. 4B). Moreover, rotenone and anti-
mycin A increased the phosphorylation of AMPK-a and
ACC and decreased the expression of p-mTOR (Fig. 4B).
Metformin decreased oxygen consumption and
intracellular ATP levels. Having identiﬁed that metformin
had similar effects on the expressions of hypoxia-induced
HIF-1a protein and AMPK as mitochondrial respiratory
inhibitors, we then directly measured the oxygen con-
sumption and intracellular ATP levels in HRPTECs treated
with 1 mmol/L metformin and 1 mmol/L AICAR under
normoxic and hypoxic conditions in medium containing
5.5 mmol/L (low) or 25 mmol/L (high) glucose for 4 h. As
shown in Fig. 4C, hypoxia decreased oxygen consump-
tion down to 76.5% of the control in normoxia, which
was consistent with the previous study (32), whereas this
response to hypoxia was blunted by the treatment of
25 mmol/L glucose (Fig. 4D). Notably, metformin signiﬁ-
cantly inhibited oxygen consumption to ,50% of controls,
independent of the oxygen conditions or the glucose milieu
(Fig. 4C and D). In addition, the results show that the trend
was for cell ATP to decrease during metformin treatment
under either normoxic or hypoxic conditions in contrast to
the enhancement of ATP levels by the treatment of AICAR
(Fig. 4E). Consistent with a previous study (33), hypoxia did
not induce ATP depletion in HRPTECs because the meta-
bolic shift to anaerobic glycolysis seems to have been sufﬁ-
cient to maintain ATP in hypoxic cells (Fig. 4E). In
contrast, 25 mmol/L glucose attenuated ATP levels and
the inhibitory effects of metformin on ATP levels in either
normoxia or hypoxia (Fig. 4F).
Diphenylene, but not N-acetylcysteine, mimics the ef-
fects of metformin on AMPK-a and mTOR phosphor-
ylation and on hypoxia-induced HIF-1a expression.
Furthermore, we examined the effects of the NADPH oxi-
dase inhibitor diphenylene iodonium (DPI) (10 mmol/L) and
the antioxidant N-acetylcysteine (NAC) (5 mmol/L) on the
expression of HIF-1a and the phosphorylation of AMPK-a
and mTOR under normoxic and hypoxic conditions for 4
h. DPI, but not NAC, inhibited hypoxia-induced HIF-1a
expression; increased the phosphorylation of AMPK-a and
ACC; and decreased the phosphorylation of mTOR (Fig. 5A).
Although DPI also has been known to inhibit the mito-
chondrial complex I (34,35), we measured NADPH content
in order to evaluate whether the inhibition of NADPH oxi-
dase by metformin was involved in the inhibitory effects of
metformin on HIF-1a expression (Fig. 5B). Both metformin
and AICAR recovered hypoxia-decreased NADPH content,
suggesting that the inhibition of NADPH oxidase could not
be attributed to the inhibitory effect of metformin.
Effects of metformin on reactive oxygen species
production in HRPTECs. To investigate whether re-
active oxygen species (ROS) production may be impli-
cated in the inhibitory effects of metformin on HIF-1a
expression, DHE staining was examined in HRPTECs. As
shown in Fig. 5C, upper panel, hypoxia decreased DHE-
associated ﬂuorescence in the low-glucose medium com-
pared with that under normoxic conditions. In the medium
containing low glucose, metformin increased DHE staining
independent of oxygen tension, as reported in the previous
study (36), in contrast to AICAR (Fig. 5C). High glucose
enhanced ROS production compared with low glucose,
and metformin decreased high-glucose–induced ROS pro-
duction, especially in normoxia (Fig. 5C, lower panel).
Thus, these observations suggested that intracellular ROS
production was not involved in the inhibitory effect of
metformin on HIF-1a expression.
Metformin restored hypoxic conditions. Because met-
formin decreased oxygen consumption in HRPTECs, we
investigated whether metformin increases intracellular
oxygen tension using a hypoxia-sensitive dye, pimonidazole
(Fig. 5D). Notably, metformin, but not AICAR, rescued the
hypoxic state in HRPTECs under hypoxic conditions. In
addition, immunocytochemical analysis conﬁrmed that
hypoxia apparently induced the nuclear expression of
HIF-1a in HRPTECs compared with those in normoxia,
and metformin inhibited hypoxia-induced HIF-1a nuclear
stainings (Fig. 5D). AICAR did not evidently alter the
expression of HIF-1a in HRPTECs under hypoxic con-
ditions (Fig. 5D). We also examined the effects of met-
formin on the state of hypoxia in the kidney (Fig. 6A and B).
The intensity of pimonidazole staining was increased in
tubular cells of the kidney cortex of ZDF rats, which was
signiﬁcantly attenuated by metformin but not by insulin.
Metformin suppressed tubular HIF-1a expression in
type 2 diabetic rats. To conﬁrm the effects of metformin
on tubular HIF-1a expression in vivo, we treated ZDF rats
with metformin for 30 weeks. As expected, ZDF rats were
hyperglycemic, and administration of metformin to ZDF
rats signiﬁcantly decreased HbA1c by 24% (P , 0.01)
(Table 1). ZDF rats had increased urinary volume and al-
bumin excretion compared with lean controls, as described
previously (23). Treatment of ZDF rats with metformin
signiﬁcantly prevented an increase in urinary albumin ex-
cretion to 58.3% of ZDF rats (P , 0.05) (Table 1). Consistent
with the lack of albuminuria, ZL rats as lean controls showed
neither glomerulosclerosis nor tubular injury (Fig. 6C, d
and e). ZL rats exhibited the immunostainings of HIF-1a
results show that cell ATP in medium containing low glucose was trend to decrease during metformin treatment under either normoxic or hypoxic
conditions in contrast to the enhancement of ATP production by the treatment of AICAR (*P < 0.05; **P < 0.01). F: In contrast, 25 mmol/L glucose
attenuated ATP levels and the inhibitory effects of metformin on ATP levels in normoxia and hypoxia.
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ZDF rats showed strong nuclear HIF-1a expression, especially
in outer medullar and cortical proximal tubules in addition
to the inner medulla (Fig. 6C, f–h), which is consistent with
previous data in human diabetic kidney (8) and in the
kidney of streptozotocin-induced diabetic rats (7). In ad-
dition, kidneys of ZDF rats showed glomerulosclerosis and
tubulointerstitial injuries, as described previously (23)
FIG. 5. A: An antioxidant, NAC, had no effect on hypoxia-induced HIF-1a protein expression. HRPTECs were treated with 1 mmol/L metformin,
NADPH oxidase inhibitors (10 mmol/L DPI), the antioxidant (5 mmol/L NAC), and metformin under normoxic and hypoxic conditions for 4 h.
NAC did not inhibit hypoxia-induced HIF-1a expression, indicating that mitochondrial ROS production was not involved in HIF-1a stabilization.
B: NADPH contents in HRPTECs. Both metformin and AICAR restored hypoxia-decreased NADPH contents. Data are expressed as means 6 SD
(n = 3). *P < 0.05. C: Effects of metformin on ROS production in HRPTECs. Intracellular ROS were measured with DHE, which produces a red
ﬂuorescence in typically nuclear localization when oxidized to ethidium bromide by O2
2. HRPTECs were treated with 1 mmol/L metformin or
1 mmol/L AICAR overnight under normoxic or hypoxic conditions in medium containing 5.5 mmol/L (low) or 25 mmol/L (high) glucose. In medium
containing low glucose, hypoxia decreased DHE staining and metformin increased DHE staining in contrast to AICAR. High glucose enhanced DHE
staining in normoxia and hypoxia. Metformin suppressed the high-glucose–induced ROS production in normoxia and did not increase DHE staining
even under hypoxic conditions and in a high-glucose milieu (original magniﬁcation 3200). D: Detection of the hypoxic state in HRPTECs. The cells
were grown on the coverslides until subconﬂuence and then treated overnight as indicated. HRPTECs under normoxic conditions showed no
staining for HIF-1a. Hypoxia induced nuclear expression of HIF-1a in HRPTECs, and 1 mmol/L metformin inhibited hypoxia-induced HIF-1a
nuclear staining. Upper panel: A total of 1 mmol/L AICAR did not affect the expression of HIF-1a in HRPTECs under hypoxic conditions. Lower
panel: Hypoxia of HRPTECs was detected by the use of pimonidazole hydrochloride. Metformin, not AICAR, increased cellular oxygen tension in
HRPTECs under hypoxic conditions. Nuclei were stained with DAPI. Original magniﬁcation 3800. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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HIF-1a was evidently decreased in kidneys of metformin-
treated ZDF rats (Fig. 6C, k and m), accompanied by
amelioration of the tubular injury (Fig. 6C, n and o), which
was in contrast to those in kidneys of insulin-treated rats,
as described in the previous study (37) (Fig. 6C, p, r–t).
Semiquantitative assessment for HIF-1a immunostaining
and injury in cortical and outer medullary tubules revealed
FIG. 6. A: Immunohistochemistry for the hypoxia marker pimonidazole. Rats were studied at 8 weeks of treatment by metformin or by insulin. Scar
bars represent 300 mm( left row) and 30 mm( right row). B: Intensity of pimonidazole staining was increased in tubular cells of the kidney cortex
of ZDF, which was signiﬁcantly attenuated by metformin treatment not by insulin. **P < 0.01. C: Immunohistochemical analysis of HIF-1a
expressions and light micrographs of sections from kidneys stained with the periodic acid–Schiff (PAS) reagent in Zucker lean control rats (ZL
rats) (a–e), nontreated ZDF rats (ZDF) (f–j), metformin-treated ZDF rats (ZDF+M) (k–o), and insulin-treated ZDF rats (ZDF+I) (p–t). In the lean
rats (a–c) and metformin-treated ZDF rats (k–m), HIF-1a–positive cells were renal tubular cells in the inner medulla, with few positive cells in the
outer medulla and the cortex. In contrast, a marked increase in tubular staining for HIF-1a was observed in the outer medulla and cortex of ZDF
rats (f and h). Lean control rats (ZL) showed no tubular and glomerular injury in kidneys (d and e). Notably, severe sclerosed glomeruli and
damaged tubules, which present cellular debris, tubular cast formations, interstitial nephritis are observed in sections from ZDF rats (i and j).
Metformin, but not insulin (s and t), ameliorated the tubular injury in the outer medulla and cortex of ZDF rats (n and o). Asterisks show the
glomeruli. Scar bars represent 300 mm at low power ﬁeld and 30 mm at high power ﬁeld. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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HIF-1a expression and ameliorated tubular injury in ZDF
rats (Table 1).
DISCUSSION
In this study, we found that metformin inhibits hypoxia-
induced HIF-1a protein expression and thus the expres-
sion of its targeted genes, probably via the inhibition of
mitochondrial respiration in HRPTECs.
Metformin has been found to activate AMPK, a major
cellular regulator of lipid and glucose metabolism (16–18).
Previous studies also have shown that metformin is an
inhibitor of complex I of the mitochondrial respiratory
chain (38,39), independent of the AMPK pathway (17,40).
To investigate the underlying mechanism(s) of the ac-
tion of metformin, we ﬁrst assessed the role of AMPK ac-
tivation in hypoxia-induced HIF-1a expression, utilizing
AICAR, compound C, and siRNA for AMPK-a1o r- a2. We
found that metformin-induced AMPK phosphorylation was
not related to HIF-1a inhibition. In addition, we show that
metformin suppresses mitochondrial respiratory function,
suggesting that the redistribution of intracellular oxygen is
involved in the inhibitory effects of metformin on HIF-1a
expression, as described in a previous study (41). Collec-
tively, our results suggest that metformin inhibits HIF-1a
expression through the suppression of mitochondrial respi-
ration described as inhibition of oxygen consumption and
intracellular ATP levels, which subsequently activates
AMPK pathways, proposing that AMPK-a is a downstream
regulator of the mitochondrial respiratory chain. That is
probably the reason that an AMPK activator, AICAR, fails to
inhibit hypoxia-induced HIF-1a expression.
AMPK activated by metformin has been reported to in-
crease glucose transporter (GLUT-1 and GLUT-4) and
glycolytic enzymes, thereby enhancing glycolytic glucose
utilization (42), and to directly stimulate glycolysis in
hypoxic or anoxic cells (43). Thus, metformin could pro-
mote Pasteur effects, which include decreased oxidative
phosphorylation and an increase in anaerobic fermentation
(44) by inhibiting mitochondrial respiration and increasing
glucose uptake mediated by AMPK activation. Although
metformin inhibits hypoxia-induced Glut-1 expression in
HRPTECs, an HIF-1a–mediated increase in glucose uptake
and metabolism during severe hypoxia is known not to be
required for cell survival using cultured mouse primary re-
nal proximal tubular cells (33). Intriguingly, high glucose
increases oxygen consumption even under hypoxic con-
ditions but fails to augment ATP production, indicating that
high glucose abolishes Pasteur effects, which are adaptive
responses to hypoxic stress, and that high glucose decrea-
ses mitochondrial efﬁciency by uncoupling oxygen con-
sumption from ATP production. An HIF-1–dependent block
to oxygen utilization results in increased oxygen availability
and decreased cell death when total oxygen is limiting (32).
Therefore, our ﬁndings suggest that in chronic hypoxia, as
seen in diabetic nephropathy, metformin may rescue the
renal proximal tubular cells from hypoxia, oxidative stress,
and energy depletion by suppressing oxygen consumption
via inhibition of mitochondrial respiratory chain complex I,
instead of HIF-1, subsequently restoring Pasteur effects,
which are impaired by hyperglycemia (Fig. 7).
In chronic kidney injury, including diabetic nephropa-
thy, hypoxia promotes the development of renal ﬁbrosis by
inducing connective tissue growth factor (CTGF) (45) and
TABLE 1





n 64 4 6
Body weight (g) 496.17 6 13.48 403 6 4.97 457 6 61.52 631 6 36.14*†‡
Food intake (g/day) 13.98 6 3.11 39.81 6 2.50* 33.63 6 9.25* 22.38 6 3.79*†‡
Fed glucose (mg/dL) 132.17 6 15.33 573.50 6 19.50* 451.00 6 116.55* 296.33 6 100.76*†‡
HbA1c (%) 3.43 6 0.27 10.38 6 0.59* 7.88 6 1.27*† 5.73 6 1.15*†‡
Urine volume (mL/day) 8.55 6 2.44 148.73 6 11.61* 85.48 6 48.77*† 32.92 6 14.07†‡
Urinary albumin (mg $ kg
21 $ day
21) 6.85 6 3.48 349.44 6 92.55* 203.80 6 121.32*§ 108.51 6 45.69*†‖
HIF-a immunoreactivity 0.0 6 0.0 2.0 6 1.16* 0.5 6 0.58§ 1.17 6 0.41¶
Tubular injury 0.0 6 0.0 3.0 6 0.0* 1.75 6 0.96*† 2.5 6 0.55*
Data are means 6 SD unless otherwise indicated. *P , 0.01 vs. lean rats. †P , 0.01 vs. untreated diabetic rats. ‡P , 0.01 vs. metformin-treated
rats. §P , 0.05; ‖P , 0.05; ¶P , 0.05.
FIG. 7. Metformin inhibits hypoxia-induced HIF-1a protein expression
through the inhibition of mitochondrial respiration. Metformin inhibits
oxygen consumption and ATP production by inhibiting mitochondrial
complex I. Subsequently, intracellular oxygen redistribution supplies
oxygen for prolyl hydroxylase, which promotes the degradation of
HIF-1a in the proteasome. ATP depletion caused by mitochondrial in-
hibition activates AMPK, which is a downstream signaling pathway
of mitochondrial respiratory chain complex. Therefore, AICAR acti-
vates AMPK pathway but fails to inhibit hypoxia-induced HIF-1a
accumulation.
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tubular cells by augmenting apoptosis of glomerular en-
dothelial cells (47) and by upregulating matrix production
and decreasing turnover in renal ﬁbroblasts (48). Very re-
cently, Kimura et al. (10) induced interstitial ﬁbrosis in the
kidney of aged VHL
2/2 mice, in which pronounced HIF-
1a expression was observed in cortical tubular epithelial
cells. They also demonstrated that the anti–HIF-1a agent
[3-(59-hydroxymethyl-2’-furyl)-1-benzyl indazole] (YC-1) ame-
liorated interstitial ﬁbrosis in unilateral obstruction kidneys
(10). We have shown that a preclinical study using ZDF rats
conﬁrmed the expression of HIF-1a in diabetic nephropathy,
which has been described as the presence of hypoxia in
previous studies (4–8), and explored the renoprotective
effects of metformin in vivo.
In conclusion, these results in vitro and in vivo indicate,
for the ﬁrst time, that the antidiabetes drug metformin
inhibits renal tubular HIF-1a expression. These data pro-
vide a novel mechanism of effects of metformin to improve
microalbuminuria in diabetic nephropathy (14), protecting
from hypoxia-induced renal ﬁbrosis by attenuating the
expression of HIF-1a (Fig. 7).
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